FDA approves personalized cellular therapy for advanced leukemia developed by University of Pennsylvania and Children's Hospital of Philadelphia

(University of Pennsylvania School of Medicine) In a landmark decision for the field of cancer immunotherapy, the US Food and Drug Administration today approved a personalized cellular therapy developed by the University of Pennsylvania and Children's Hospital of Philadelphia for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news